EraGen Biosciences and Illumina are combining technologies to advance molecular diagnostic offerings. EraGen Biosciences will have access to Illumina’s BeadXpress platform for the development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its own MultiCode®-PLx technology. Illumina has licensed EraGen’s MultiCode-PLx platform for the life sciences, research, and clinical markets.

Previous articleHow Biotech Unions Could Save Companies and Revitalize Pipelines
Next articleScripps Research Institute to Use ISCO’s Parthenogenetic Stem Cells